whoslets

Thoratec Corporation (Nasdaq: THOR), a existence conductor in products to treat
cardiovascular disease, today said that the FDA has approved an IDE
(Investigational Device Exemption) supplement that allows enrollment of up to an additional 90 patients in the Link-to-Transplantation (BTT) arm of the company’s HeartMate II Phase II nuisance under a Continued Access Etiquette (CAP).

The primordial trial design for the BTT arm called also in behalf of enrollment of 133
patients. As of April 26, 2006, the company reported that 115 patients had
been enrolled in the BTT arm of the chew over. Forgiving enrollment under the CAP can create at the 40 centers participating in the trial every now the initial 133 patients are enrolled, subject to IRB approvals at the centers. The CAP patients will be enrolled and followed under the card protocol of the pivotal misfortune. The as well of these patients choose not affect the timing
for the company’s planned concession of a PMA (PreMarket Approval)
Supplement seeking FDA approval of the HeartMate II in the service of the BTT indication.

The HeartMate II is a continuous flow design designed to minister to
long-label cardiac support for advanced-stage heart failure patients. An
implantable LVAS (Left Ventricular Assist System) powered by a rotary
pumping mechanism, it is significantly smaller than currently approved
devices. The HeartMate II is designed to have a much longer functional life than other approved devices and to operate more artlessly and quietly. The device provides blood stream through the circulatory system on a continuous base with only one moving part. It is also smaller and easier to implant than pulsatile devices.

Thoratec Corporation is a far-out commander in hemodyanmic restoration
therapy-developing products to treat cardiovascular disease. The company’s product up for includes the Thoratec(R) VAD and HeartMate LVAS with more than 10,000 devices implanted in patients pain from kindness failure. Thoratec’s offshoot line also includes the Vectra(R) VAG (Vascular Access Graft) to go to patients undergoing hemodialysis. Additionally, itsbInternational Technidyne Corporation (ITC) group supplies blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. In regard to more intelligence, visit the company’s web sites at http://www.thoratec.com or http://www.itcmed.com.

Some of the above-named paragraphs, particularly but not exclusively
those addressing timelines and milestones for clinical trials, check
pushy-looking statements within the meaning of Section 27A of the
Securities Feigning of 1933 and Section 21E of the Securities Exchange Exploit of
1934. These statements can be identified by the words, “expects,”
“projects,” “hopes,” “believes,” “could,” and other similar words. Actual
results, events or performance could differ materially from these
forward-looking statements based on a breed of factors, many of which are beyond Thoratec’s control. That being so, readers are cautioned not to raise undue reliance on these statements. Investors are cautioned that all such statements count in risks and uncertainties, including risks related to the results of, enrollment in and timing of clinical trials including the
HeartMate II and the regulatory approval processes. Forward-looking
statements contained in this press release should be considered in vacant of these factors and those factors discussed from once upon a time to speedily in Thoratec’s out of the closet reports filed with the Securities and Exchange Commission, such as those discussed below the heading, “Risk Factors,” in Thoratec’s most modern annual report on Form 10-K and three-monthly gunfire on Form 10-Q. These forward-looking statements speak only as of the date hereof. Thoratec undertakes no obligation to publicly disenthral the results of any revisionsto these hurry-looking statements that may be made to reflect events or circumstances after the season hereof, or to consider the instance of unanticipated events.

Thoratec Corporation
http://www.thoratec.com/

The Supplemental York Times on Saturday examined pay-for-conduct pricing systems and endanger-sharing experiments in the U.S. and abroad since costly-payment medication drugs. Under a proposed arrangement between the Johnson & Johnson constituent Janssen-Cilag and Britain’s nationwide health service, the government power would pay as a replacement for the company’s cancer deaden Velcade “only championing people who benefit from the remedy.”

Initially, an advisory board unquestioned that Velcade — approved to behave relapses of multiple myeloma, a bone marrow cancer — was not cost effective and that it should not be covered by the nationalist haleness service. Philosophical groups and the companions won an appeal of the decision and the government agency was forced to reconsider coverage of the treatment. J&J then proposed the program as a avenue to be enduring the treatment designated as cost effective.

Inferior to the scheme, all patients would be eligible for four cycles of treatment, which cost yon $24,000. If the tumors show up to shrink, as determined by a blood check, treatment would continue and the health service would cover the outlay. If tumors do not shrink, treatment with Velcade would stop and the company would indemnify the regulation for money spent on the drug. Be that as it may, the retinue and control disagree on how much the tumors must shrink for the drug to be considered favourable. GlaxoSmithKline says it has reached alike resemble agreements with two European nations, although the fellowship would not blurt out which countries or drugs were involved.

According to the Times, such proposals “may signal the pharmaceutical industry’s willingness to lead toward a recent get one’s just deserts-concerning-performance paradigm — in which a drug’s price would be based on how well it worked and might be adjusted up or down as new evidence came in.” However, “[i]t is everywhere a beyond too momentarily to hillock whether such a pricing paradigm can actually work, in particular because it can be troubling in many cases to measure how pleasing a drug is working,” and the “approach would undoubtedly be most usable in countries, like Britain, where the government is the primary payer,” the Times reports.

U.S. Programs
Lee Newcomer, senior vice president for oncology at United Healthcare, said such “risk-sharing” deals would be difficult to reach in the U.S. because there is “no way we could ask for it and have any leverage.” He added that state regulations and marketplace pressures make it very difficult for a U.S. insurer to deny coverage for a drug approved by FDA, regardless of cost.

However, United Healthcare is trying a risk-sharing experiment with Genomic Health, involving a test that helps determine whether a woman with early stage breast cancer would benefit from chemotherapy. Under the agreement, the insurer will pay for the test for 18 months, while Genomic monitors how many women still receive chemotherapy after the test suggests they do not need such treatment, according to Newcomer. Genomic will lower the price of the test if it does not have the intended impact on actual medical practice, according to the Times.

Newcomer said, “The point is to try to make the manufacturer responsible for how their product is used in the medical marketplace.”

Meanwhile, Sean Tunis, a former chief medical officer of CMS and director of the not-for-profit Center for Medical Technology Policy, said he was asked by a U.S. biotechnology company for his opinion on whether to offer a money-back plan on a new cancer drug. “I and others suggested a money-back guarantee on a cancer drug looked silly,” he said, adding, “‘Oh, I’m sorry your grandma died. Here’s your money back’” (Pollack, New York Times, 7/14).

“Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on Velcade.

Insulin, a hormone released in elephantine quantities when food is consumed, is reduced by 50% only three to five minutes later. Come what may, if the cell’s internal become debilitated disposal method malfunctions, illnesses such as Alzheimer’s or Parkinson’s disease may happen. To prevent this from happening, the complex alter of protein dishonour first needs to be fully understood at an atomic level so that appropriate drugs can be developed. Biochemists at Frankfurt University, collaborating with an international team of scientists have just taken an grave stoop proceed close to unravelling the workings of this organization. In the current printing of the painstaking magazine Cosmos they report finding the long-awaited receptor for ubiquitin on the proteasome. This receptor may well boon out to clothed a key role in fighting tumours.

“A discovery of this sort happens only once in a researcher’s lifetime” comments Professor Ivan Dikic, in whose party at the Begin for Biochemistry the momentous finding was made. The editors of “Nature” agree and be suffering with accepted two manuscripts describing this discovery: an article (leading manuscript in the issue) and a letter (regular publication). The Institute’s head Professor Werner Müller-Esterl states “We are delighted by his success of a member of our Cluster of Excellence on Macromolecular complexes. This rank of honour is at best achieved by one in a thousand scientists”.

How on earth, things were looking very different only a year ago when it appeared that the research groups elaborate in this project - in Frankfurt, Munich, Minnesota and Harvard - were treading inundate. The scientists were hoping to answer nature of the portal protein from yeast using protein crystallography but the protein refused to crystallize. However, Koraljka Husnjak, a postdoctoral researcher inaugurate a way to isolate the ubiquitin binding domain in the mammalian protein, that was amenable for instant crystallization and resulting determination of its structure.

Already some 30 years ago, the basic mechanism of cellular waste disposal was elucidated by three scientists, Aaron Ciechanover, Avram Hershko, and Irwin Rose, fitted which they won Nobel Prize in Chemistry in 2004. Since then it has been known that proteins apt for disposal are marked with ubiquitin molecules, which are present completely the cell. They reach the barrel-like proteasome complex via ’shuttle’ molecules or thoroughly diffusion. On the upper side of the proteasome there is a big-hearted of gatekeeper’s stick with a narrow entrance leading to an inner congress, where belligerent enzymes split the protein. But pre-eminent the protein is subjected to a constricting rule modus operandi to ensure that it is just so destined during the shredder. If the gatekeeper - a receptor - recognizes that the protein is tagged with ubiquitin, the tagged protein is unfolded and can then pass through the narrowed pit. While this takes place the ubiquitin separates from the protein, keen to be re-used. Until now, single one such gatekeeper, a proteasomal receptor called Rpn 10, was known. The scientists then conducted experiments to genetically remove Rpn 10 from the room and were surprised to discover that the proteasome continued to act normally. This led them to suspect that there ought to be an additional protein in the cell, which compensates in the absence of Rpn 10 and serves a similar purpose. This has now been discovered: protein Rpn 13.

According to Koraljka Husnjak the to begin breakthrough occurred about four years ago, when they institute into the open that ubiquitin binds to a subunit in the gatekeeper’s lodge. “So it became clear to us that the proteasome subunit muscle act as ubiquitin receptor on the proteasome. But in front of all we had to illuminate this binding site’s dinner and understand the details of the binding alter at an atomic level”. Ivan Dikic then asked other leading global groups for their expertise in help to work this complex research problem. The X-ray structural analysis was carried out by Prof. Michael Groll and his group at the Complicated University in Munich, and a group led by Prof. Kylie Walters at the University of Minnesota, Minneapolis undertook the NMR system work. As soon as the binding procedure had been arranged at an atomic level, Professor Finley and his group at Harvard Medical School conducted experiments with a number of yeast strains in which they were able to prove that in living cells the process was indeed equal to that already suggested by the structural model.

The discovery of this second receptor on the proteasome is of particular point in cancer scrutinization since it has the potential to be blocked by specific drugs. This would then prevent the proteins in the cell from being broken down. Since developing cancer cells depend on the ruin of specific proteins in signalling cascades, which be published critical for tumour cell survival and proliferation, the cancer cells would no longer be skilled to multiply. It is liable to that both these receptors behave selectively to undisputed groups of proteins. So even if single is blocked, the other continues to ensure that the proteins that are no longer needed nevertheless still gain access to the proteasome.

—————————-
Article adapted by Medical Telecast Today from inventive press unfetter.
—————————-

Source: Professor Dr. Ivan Dikic

Goethe University Frankfurt

A molecule in the corpse could carry on the key to explaining why people who exercise regularly are less likely to have illnesses such as prototype 2 diabetes. The enzyme, called AMPK, acts as the body’s ‘fuel gauge,’ playing a crucial role in regulating energy intake, utilisation and storage. Decision senseless exactly how it works could servants to explain how put to use affects the league at the molecular supine.

In a review article published in the journal Cell Metabolism, Professor David Carling and colleagues at the Medical Research Council Clinical Sciences Centre at Imperial College London based at Hammersmith Hospital, describe current research on AMPK. Research on this molecule will increase our understanding of the effect that exercise has on metabolic activity in the cells of the body, and could explain the link between regular exercise and onset of type 2 diabetes.

“The benefits of exercise as a weight-loss tool are very well known, but exercise also has other medical benefits,� comments Professor Carling. “Illnesses such as diabetes and heart disease have all been shown to be less prevalent in people who do moderate amounts of exercise, and it is looking likely that AMPK plays a key role.�

Found throughout the body, AMP-activated protein kinase (AMPK) is one of the gatekeepers in the process of energy production and expenditure in the cell. Higher levels of AMPK in muscle tissue increase energy expenditure and glucose uptake, a process which goes wrong in diabetes. AMPK in the brain has a different effect - in laboratory studies lowering AMPK levels in the brain leads to a decrease in appetite and food intake.

Professor Carling’s group has been awarded a £335,000 EU grant in order to continue their research on the cellular actions of AMPK. The project brings together 25 other groups from 13 countries, and involves a number of different approaches, including genetic studies in humans. “By being able to piece together the complex pieces in the molecular jigsaw, we can better understand how our metabolism functions in health and disease,� adds Professor Carling. “We expect the results to have important implications for diets and lifestyles of the future. Exercise will of course continue to be a cornerstone of healthy living, but it is likely that we will be able to design drugs that interact with AMPK as an alternative when exercise is not possible or when dietary interventions have failed�.

http://www.hhnt.nhs.uk/

Sens. Tom Harkin (D-Iowa) and Arlen Specter (R-Pa.) on Wednesday removed a provision from the monetary year 2008 Labor-HHS-Education appropriations bill (S 1710) that would clothed expanded funding for human embryonic stanch cubicle research in hope that President Bush would drop his denial threat, CQ Today reports. The provision would sire allowed researchers to use federal funds for work with any embryonic peduncle chamber face created before June 15, 2007 (Wayne, CQ Today, 10/17).

The White Prostitution earlier on Wednesday said Bush would prohibition the weigh because of the embryonic stem cubicle provision and because it contains “irresponsible and excessive” spending (Taylor, AP/Google.com, 10/17). Federal funding for the treatment of embryonic retard cubicle research currently is allowed at best as far as something dig into using embryonic stem apartment lines created on or in the forefront Aug. 9, 2001, under a policy announced by Bush on that date. Bush has twice vetoed bills that would include allowed federal funding on account of dig into using reborn embryonic withstand cell lines (Kaiser Daily Women’s Health Policy Tell of, 10/17).

The provision to dilate funding for embryonic retard cell research was removed “in the spirit of compromise” and because “we wanted to screen that we are zealous to compromise,” Harkin said, adding, “We’re willing to try to fulfil the president halfway.” According to CQ Today, the removal of the provision is unlikely to assuage Bush’s objections to the bill (CQ Today, 10/17). The House has approved its understanding of the Labor-HHS-Erudition appropriations bill (HR 3043), but the delimit did not pass with a veto-validation majority. Bush has threatened to veto the Forebears bill because it contains $11 billion more than he requested. The Senate legislation contains close by $9 billion more than Bush requested (Kaiser Daily Health Way Report, 10/2).

Reprinted with kind permission from http://www.kaisernetwork.org. You can because of the unconditional Kaiser Daily Condition Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Day after day Fettle Policy Report is published for kaisernetwork.org, a enfranchise repair of The Henry J. Kaiser Kindred Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights standoffish.

Bob Hilliard, attorney at Corpus Christi, Texas-based Hilliard & Munoz, represents a sprinkling Guidant Corp. patients:

“What they knew and when they knew it are the questions facing Guidant Corp., which has recalled nearly 90,000 implantable cardiac defibrillators in the pattern month and is under examination by the FDA. The companions has known for years that these defibrillators had potentially life-looming flaws. Officials set up admitted they knew about the problems conducive to more than three years, yet did not dream the warning was enough to warn doctors. These patients have compassion conditions, and now they’re faced with either customary under the slash again or by the skin of one’s teeth hoping their defibrillator isn’t defective.”

ProfNet
Ste 200, 888 Veterans Highway
Hauppauge, NY 11788
Coalesced States
http://www.profnet.com

The Unripe York Times on Friday examined how at least part of the new Medicare medicament panacea benefit might not necessarily be working as “Congress intended,” as some employers who provide retiree direction drug coverage are saying that retirees who choose to enroll in the new Medicare drug improve will lose all owner-sponsored fettle benefits. For the purpose instance, Boeing, in a correspondence literature recently sent to 100,000 retirees and their dependents, said, “[Y]our Boeing medicine dose coverage is more generous than standard Medicare remedy opiate coverage.” How in the world, the letter adds, “Your Boeing remedy drug coverage is shard of your Boeing retiree medical scenario. If you cancel your Boeing preparation drug coverage” to enroll in the fashionable Medicare drug allowances, “your Boeing medical coverage also will be canceled.” According to the Times, other companies — such as GM, Caterpillar, Verizon Communications, SBC Communications and the Southern Company — are informing retirees that their company medicament benefits are as saintly as or superior to the Medicare yardstick drug promote. In many cases, “plan sponsors are saying, ‘If you join Medicare Put asunder give up D, you will be out of our plot,’” Edward Kaplan, a senior haleness control counselor at the Segal Company, said. GM is a “notable exception” in that it is allowing retirees to memorize their health benefits even if they enroll in the new Medicare drug emoluments, the Times reports.

Explanation
According to the Times, the companies’ decision to drop all health benefits for retirees who enroll in the Medicare drug benefit might “be understandable.” Many employers provide drug benefits within a comprehensive medical benefits package and generally do not charge a separate premium for drug coverage. Some employers say it would be difficult to separate the drug coverage from the larger benefits packages they currently offer. In addition, companies have an incentive to continue to provide retiree drug coverage because they will receive a subsidy from CMS for each retiree enrolled in their drug plan. Companies “have shown little interest” in continuing to provide other, “increasingly expensive” medical benefits to retirees if it means they will lose the subsidies, the Times reports. The subsidies will equal 28% of a retiree’s drug costs, from $250 to $5,000 in 2006. The average subsidy will be about $668 per qualified retiree in 2006 with a maximum of $1,330 per retiree, according to the Bush administration. However, with the subsidy program expected to cost $71 million between 2006 and 2013, some analysts say it could face elimination under congressional cost-cutting efforts. Moreover, the subsidy, “[e]ven at the current level, … is not enough to offset employers’ rising health costs,” though companies such as Dow Chemical and IBM are using it partly to offset monthly premium increases for retiree health benefits (Freudenheim/Pear, New York Times, 11/4).

Electronic Prescribing
In related news, CMS has announced new rules for electronic prescribing standards under the Medicare drug benefit, CQ HealthBeat reports. In a news release, CMS Administrator Mark McClellan said, “We are making e-prescribing easier to implement, to accelerate the use of e-prescribing in Medicare and throughout the nation’s health care system.” He said all Medicare prescription drug plans must comply with the new standards by Jan. 1, 2006, when the new benefit begins (CQ HealthBeat, 11/3).

“Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Two University of Virginia School of Nostrum researchers have been awarded grants from the National Establish of Allergy and Infectious Diseases to develop treatments and tests in return some rapidly emerging trouble spots in the area of gastrointestinal diseases.

Under these cooperative agreement (U01) grants, one scientist plans to develop a single test to tag more than 20 different food and waterborne pathogens while the minute at one’s desire create a single treatment which could protect people from comely infected with more than 20 potential pathogens.

These pathogens have ripen into splendidly known to the ordinary buyers in recent years, most importantly from cases of E. coli bacteria infecting the food supply. In 2006, three people died and hundreds more were sickened after eating E. coli contaminated spinach. Possibly the best known modern circumstance of large-scale public infection occurred in Milwaukee, Wisconsin in 1993. That year, more than 400,000 residents were sickened by Cryptosporidium parvum, a leech which infiltrated the city’s water cache. More than 100 people died as a rule result of being infected with the parasite.

“Detecting an outbreak of E. coli in the nourishment supply or cryptosporidium in the water give as lickety-split as attainable is vital if we are accepted to certify the safety of what we eat and drink,” says Dr. Eric Houpt, associate professor of medicine at the University of Virginia Devotees of Panacea. “The take exception to is developing a particular test for the treatment of the most common pathogens as opposed to just one test as regards one pathogen.”

Houpt will lead the team of researchers in developing the test, which includes scientists from Michigan Stately University, the Commonwealth of Virginia Division of Consolidated Laboratory Services, Kilimanjaro Christian Medical Center in Tanzania and the clandestinely sector. The resulting diagnostic exam could then be deployed to medical settings such as hospitals, clinics, or field sites.
Dr. Paul Hoffman, professor of medicine at the University of Virginia, is using his $2.6 million grant to develop another generation antiparasitic/antibacterial therapeutics to manipulation of infections caused by Giardia, Cryptosporidium, Campylobacter, Entamoeba and Clostridium difficile.

“These are all extremely nasty parasites to pick up and for divers people, especially people with weaker exempt systems, they can prove fatal because of the debilitating diarrhea associated with infection,” Hoffman says.

Working with pharmaceutical companies and University of Virginia professor of chemistry Timothy Macdonald, Hoffman’s group plans to use a novel drug target simple in parasites and undoubted bacteria by chemically modifying available drugs to improve their efficacy and distend the conditions they can treat.

“If we can put this medication in a unwed pill, we can prevent people from becoming ill from these parasites before they are exposed and treat them if they have been infected,” Hoffman says. “This could be used in preparation for a natural cataclysm where we know there will be parasitic outbreaks or in reply to a bioterrorism event.”

Houpt and Hoffman are optimistic the test and the treatment could be likely for testing within three years.

—————————-
Article adapted by Medical News Today from original newswomen put out.
—————————-

Commencement: David Foreman

University of Virginia Robustness Plan

A groundbreaking study led by Northwestern University researchers has demonstrated that a protein called alphaB-crystallin, which normally protects cells from stress damage, triggers events that may belief chest cancer when overactive.

Breast cancer is the most common cancer in women and is responsible for over 400,000 deaths annually in women throughout the world. Most of these deaths are the result of aggressive breast tumors that often fail to respond to current treatments.

The researchers found that women whose breast tumors express the alphaB-crystallin protein have a shorter survival, suggesting that alphaB-crystallin may be a useful molecular marker to identify women with aggressive breast cancer and to develop new targeted cancer therapies.

The study, which was published in the January issue of the Journal of Clinical Investigation, was led by Vincent L. Cryns, M.D., associate professor of medicine and director of the Cell Death Regulation Laboratory at Northwestern University Feinberg School of Medicine, and a researcher at The Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Cryns and colleagues found that introducing the alphaB-crystallin gene into non-cancerous breast cells transformed them into breast cancer cells. These experiments took advantage of a powerful technique to grow breast cells as three-dimensional (3D) gland-like structures that are similar to those present in the normal breast. However, when the researchers introduced alphaB-crystallin into non-cancerous breast cells, the cells started growing uncontrollably and formed enlarged 3D masses that resemble breast tumors.

The experiments were conducted by Jose V. Moyano, a post-doctoral fellow in the Cryns lab, who was lead author on the study.

“Basically, breast cancer cells have hijacked alphaB-crystallin, a protein that normally protects cells against stress injury and death, and used it to promote their uncontrolled growth,” Cryns reflected.

The investigators also showed that alphaB-crystallin activates a key molecular pathway, the MEK-ERK pathway, that leads to unrestrained cell growth in cancer, and that drug inhibitors of this pathway block the cancerous effects of alphaB-crystallin.

“Currently, we don’t have any targeted treatments like tamoxifen or Herceptin for the aggressive type of breast tumors that express alphaB-crystallin. Our results suggest that these tumors may respond to drugs that block this important pathway activated by alphaB-crystallin,” Cryns said.

Cryns’ laboratory group also observed that non-cancerous breast cells genetically manipulated to express alphaB-crystallin form aggressive breast tumors when injected into mice, confirming their malignant nature.

What’s more, the team found that these mouse tumors were similar in many respects to human breast tumors which express alphaB-crystallin, suggesting that this mouse model may be useful for testing new treatments for these poor-prognosis tumors. Indeed, the researchers are currently exploring whether drug inhibitors of the MEK-ERK pathway block breast tumor growth in mice.

Collaborating with Cryns and Moyano were Torsten O. Nielson and Dmitry Turbin, University of British Columbia, Vancouver; and Charles M. Perou and Gamze Karaca, University of North Carolina at Chapel Hill. Other members of the research team at Northwestern University were Fruma Yehiely, Joseph R. Evans, Feng Chen, Meiling Lu, Michael E. Werner, Leslie Diaz and Elizabeth Wiley.

http://www.northwestern.edu/

Use of the widely used birth control
pill, ORTHO TRI-CYCLEN(R) LO (norgestimate/ethinyl estradiol) Tablets,
resulted in significantly degrade rates of breakthrough bleeding and spotting
in a indefinite variety of women compared to another low-dose combination nativity
control pill, according to data presented today at the 55th Annual Clinical
Congregation of The American College of Obstetricians and Gynecologists
(ACOG).(1)

This inquiry compared the breakthrough bleeding and spotting profiles
of two low-dispense origination control pills, containing either 25 mcg or 20 mcg of
ethinyl estradiol and differing progestins, in women across a range of ages
and weights.

Breakthrough bleeding and spotting, which refers to strange or
unexpected bleeding between periods, is a side effect associated with the
use of birth control pills, especially low-dose pills, and is the cardinal
cause of dissatisfaction and discontinuation of oral contraceptive use. It
most commonly occurs in the start with few months of taking a unknown pill, and
commonly ceases at a go the portion adjusts to the hormonal dosage.

“Breakthrough bleeding is a bothersome side effect of using the Pill,”
said lead investigator Raymond Moss Hampton, M.D., Texas Tech University
Manner of Remedy. “These observations demonstrate that women using ORTHO
TRI-CYCLEN LO, an basic, low dose combination birth dominate pain in the neck, deceive
significantly less breakthrough bleeding, regardless of time or clout.”

The findings are based on a retrospective analysis of data from a
randomized clinical hard luck evaluating the safety and efficacy of ORTHO TRI-
CYCLEN LO (norgestimate/ 25 mcg ethinyl estradiol) compared to Loestrin(R)
Fe 1/20 (norethindrone acetate/20 mcg ethinyl estradiol) tablets. The swot
evaluated the extent of breakthrough bleeding and spotting in 1,506
women using ORTHO TRI-CYCLEN LO versus 1,057 women using norethindrone
acetate/20 mcg ethinyl estradiol tablets for up to 13 unremitting menstrual
cycles.

All women were between the ages of 18 and 45 and weighed between 90 and
240 pounds. Women were stratified by duration and by weight, and all groups were
analyzed to resolve the degree of breakthrough bleeding and spotting
by cycle. Cycle six data were presented as representative figures for this
analysis.

Based on this study analysis, a lower prevalence of breakthrough
bleeding and spotting was observed for women using ORTHO TRI-CYCLEN LO
versus norethindrone acetate/ethinyl estradiol regardless of lifetime or tonnage.

ORTHO TRI-CYCLEN(R) LO (norgestimate/ethinyl estradiol) is indicated
for the prevention of pregnancy in women who choice to use oral
contraceptives as their method of contraception. It is a low-dose,
tri-phasic hormonal birth control pill that provides high efficacy in
pregnancy prevention with a low incidence of common side effects.

Loestrin Fe 1/20 is marketed by Barr Pharmaceuticals, Inc.

Superior Safety Information

Thoughtful as well as insignificant side effects press been reported with the use
of oral contraceptives. Serious risks, which can be life inauspicious,
include blood clots, stroke and heart attacks, and are increased if you
smoke cigarettes. Cigarette smoking increases the jeopardize of serious
cardiovascular side effects, firstly in strife closed 35. Women who reason
oral contraceptives are strongly advised not to smoke. Some women should
not turn to account the Pill, including women who receive blood clots, certain cancers, a
history of quintessence attack or stroke, as well as those who are or may be
pregnant. The Pharmaceutical does not protect against HIV or sexually transmitted
diseases.

Gladden investigate the full U.S. Prescribing Information at http://www.thepill.com.

Upon Ortho Women’s Strength & Urology

Ortho Women’s Health & Urology, a Split of Ortho-McNeil
Pharmaceutical, Inc., is a concert-master in the fields of women’s health and
urology, celebrating 75 years of partnering with women. Ortho Women’s
Health & Urology is committed to dollop people actual healthier lives and to
meeting the needs of providers and patients with products such as ORTHO
EVRA(R) (norelgestromin/ethinyl estradiol transdermal system), ORTHO
TRI-CYCLEN(R) LO (norgestimate/ethinyl estradiol), DITROPAN XL(R)
(oxybutynin chloride), and ELMIRON(R) (pentosan polysulfate sodium). For
more information on these products, parturition control, bladder health or
general women’s vigorousness issues, please upon http://www.orthowomenshealth.com.

References

(1) Raymond Moss Hampton, MD; Huabin F. Zhang, MD, MPH; Christopher
Barnowski, MD; George J. Sorry, PhD, MPH. Bleeding Patterns With Mono- and
Triphasic Second-rate-measure Ethinyl Estradiol Combined Spoken Contraceptives. Notice
presenting at: 55th Annual Clinical Meeting of The American College of
Obstetricians and Gynecologists, May 5-9, 2007, San Diego, CA.

Ortho-McNeil Pharmaceutical, Inc.
http://www.orthowomenshealth.com

Inspection drug news on Ditropan XL; Elmiron; Estradiol.